Gain Other Current Liab from 2010 to 2025

GANX Stock  USD 1.91  0.09  4.50%   
Gain Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Gain Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.73 and arithmetic mean of  795,516. View All Fundamentals
 
Other Current Liabilities  
First Reported
2019-03-31
Previous Quarter
3.4 M
Current Value
2.5 M
Quarterly Volatility
1.1 M
 
Covid
Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 172.5 K, Net Interest Income of 666.2 K or Depreciation And Amortization of 100.9 K, as well as many indicators such as Price To Sales Ratio of 842, Dividend Yield of 0.0 or PTB Ratio of 3.2. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Gain Therapeutics Correlation against competitors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Gain Therapeutics over the last few years. It is Gain Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Gain Other Current Liab Regression Statistics

Arithmetic Mean795,516
Geometric Mean398,378
Coefficient Of Variation117.06
Mean Deviation786,747
Median159,513
Standard Deviation931,234
Sample Variance867.2B
Range2.4M
R-Value0.86
Mean Square Error248.3B
R-Squared0.73
Significance0.000023
Slope167,440
Total Sum of Squares13T

Gain Other Current Liab History

20252.5 M
20242.4 M
20232.1 M
2022M
20211.2 M
2020767.4 K
2019253.7 K

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities2.4 M2.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.